# Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer

> **NCT02621398** · PHASE1 · COMPLETED · sponsor: **Rutgers, The State University of New Jersey** · enrollment: 23 (actual)

## Conditions studied

- Stage II Non-Small Cell Lung Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **DRUG:** Carboplatin
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02621398
- **Lead sponsor:** Rutgers, The State University of New Jersey
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-04
- **Primary completion:** 2019-10-24
- **Final completion:** 2024-02-29
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2025-12-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02621398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02621398, "Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02621398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*